AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TMDX · NASDAQ · Medical - Devices

TransMedics Group (TMDX)

Pairs warm organ perfusion systems with end-to-end transplant procurement and logistics.

$88.03

After hours−0.08 (−0.09%)

At close$88.11(+0.94%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	66	81	97	114	109	122	144	157	144	161	174	190
Cost of revenue	26	33	37	45	48	50	55	61	59	67	73	77
Gross profit	41	48	60	69	61	72	88	97	85	93	101	113
	69	45	47	57	57	63	61	60	61	72	88	89
Research & development	38	11	11	14	14	16	17	16	15	21	25	32
	31	35	36	43	43	47	44	44	46	51	57	58
Selling & marketing	0	0	0	0	0	0	0	0	1	1	1	0
General & administrative	31	35	36	43	43	47	44	44	45	50	56	0
Other expenses	0	0	0	0	0	0	0	0	0	0	6	0
Operating income	−28	3	12	13	4	9	27	37	23	21	13	24
	1	1	0	0	0	−2	−1	0	0	0	−5	−4
Interest income	5	5	4	3	3	3	0	3	0	0	3	3
Interest expense	4	4	4	4	4	4	3	3	3	3	7	7
Other non-operating income	−5	−5	−4	−3	−4	−2	−3	−3	−3	−4	−2	−3
Income before tax	−27	4	12	12	4	7	27	36	23	22	8	19
Income tax expense	−2	0	0	0	0	0	1	1	−1	−84	1	5
Net income from continuing operations	−25	4	12	12	4	7	26	35	24	105	7	15
Net income	−25	4	12	12	4	7	26	35	24	105	7	15
EPS, basic	−$0.78	$0.12	$0.37	$0.37	$0.13	$0.20	$0.76	$1.03	$0.71	$3.08	$0.21	$0.42
EPS, diluted	−$0.78	$0.12	$0.35	$0.35	$0.12	$0.19	$0.70	$0.92	$0.66	$2.59	$0.20	$0.41
Weighted average shares, basic	33	33	33	33	33	34	34	34	34	34	34	35
Weighted average shares, diluted	33	34	35	35	36	35	40	41	41	41	36	41
EBITDA	−21	11	20	20	13	16	36	46	33	32	28	27
Depreciation & amortization	2	4	4	5	5	6	6	7	7	7	12	0
EBIT	−23	7	16	16	8	11	30	40	27	25	16	27